Core Viewpoint - The listing process of Kanghua Co., Ltd. on the Beijing Stock Exchange is shrouded in uncertainty due to a series of unconventional operations and ongoing inquiries from regulatory authorities, leading to concerns about the company's fundamentals and sincerity in the listing process [1][7]. Financial Performance - Kanghua Co., Ltd. met the financial standards for listing by reporting a net profit of 104 million yuan and a return on equity of 9.3% for 2024, but its 2023 return on equity was only 6.56%, indicating reliance on a single year's data for compliance [2][8]. - In the first half of 2025, the company reported a revenue of 435 million yuan, a year-on-year decrease of 19.32%, and a net profit of 46 million yuan, down 23.4% [2][8]. Inventory and Revenue Recognition Concerns - The inventory level of major distributors reached 26.58% of their procurement by June 2025, significantly higher than 11.73% at the end of 2023, raising doubts about the authenticity of revenue recognition [10]. - By September 2025, only about 36% of the inventory from June had been sold, which is below historical levels, suggesting potential issues with normal business practices [10]. Governance Issues - The company faces significant governance concerns, including potential conflicts of interest due to family-controlled enterprises engaging in similar businesses, which complicates the independence of operations [5][12]. - Kanghua Co., Ltd. has been criticized for a lack of transparency and competitive processes in asset disposal, particularly regarding a write-off of 97.31 million yuan in inventory, raising questions about the fairness and safety of asset recovery [6][13]. Fundraising and Project Viability - The company initially planned to raise 562 million yuan for five projects but reduced the amount to 368 million yuan and cut the number of projects to three after receiving regulatory inquiries, indicating potential issues with project viability and necessity [4][11]. - The reduction in fundraising and project scope has led to skepticism about the company's actual need for capital and the rationale behind its IPO [4][11].

Core Viewpoint - Shandong Kanghua Biological Medical Technology Co., Ltd. (Kanghua) is facing significant scrutiny in its IPO process on the Beijing Stock Exchange, particularly regarding its declining performance, the necessity of its fundraising projects, and related party transactions [1][3]. Financial Performance - Kanghua's revenue has sharply declined from 1.48 billion yuan in 2022 to 738 million yuan in 2023, and further to 729 million yuan in 2024, indicating a near halving of revenue in 2023 [3][5]. - Net profit also decreased significantly from 270 million yuan in 2022 to 69 million yuan in 2023, with a slight recovery to 123 million yuan in 2024, still less than half of the 2022 figure [3][5]. - The company's total assets decreased from approximately 1.48 billion yuan in 2022 to about 1.39 billion yuan in 2024, while shareholder equity showed a slight increase from 1.06 billion yuan in 2023 to 1.17 billion yuan in 2024 [4]. Business Segments - Kanghua's main revenue source, Point-of-Care Testing (POCT), saw a drastic drop in emergency business revenue, plummeting by 86.77% from nearly 900 million yuan in 2022 to 119 million yuan in 2023, with no revenue from this segment in 2024 [4][5]. - Regular business POCT reagent revenue growth has also slowed, with a 65.17% increase in 2023 dropping to just 10.37% in 2024, and a decline in the first half of 2025 [5][10]. Fundraising and Investment Projects - Kanghua has reduced its fundraising projects from five to three, cutting the total fundraising amount from 562 million yuan to 368 million yuan, a decrease of 35% [6]. - The company has faced questions from regulators regarding the necessity of its fundraising projects, especially after the reduction, which suggests previous overestimation of funding needs [6][10]. Research and Development - Kanghua's R&D expenditure as a percentage of revenue has been lower than that of comparable companies, with figures of 6.88%, 11.56%, and 11.10% from 2022 to 2024, compared to industry averages of 9.17%, 17.23%, and 17.77% [11][12]. - Despite the lower R&D investment, marketing expenses have surged, with promotional costs rising from approximately 13 million yuan in 2022 to over 64 million yuan in 2024, raising concerns about the company's focus on marketing over R&D [12][13]. Market Environment - The global IVD market is experiencing a downturn, with a 30% decline in 2024 due to the normalization of demand post-pandemic, leading to increased competition in a saturated market [10]. - Major players in the industry, such as Maike Biological and YHLO, have reported net profit declines exceeding 70%, indicating a challenging environment for Kanghua as it attempts to expand despite its own declining performance [10].

Group 1 - The core point of the article is that Kanghua Co., Ltd. has significantly reduced its fundraising amount and the number of investment projects in its IPO plan amid regulatory scrutiny, with the total fundraising amount decreasing from 562 million yuan to 368 million yuan, a reduction of 35% [1][23][30] - Kanghua Co., Ltd. received a second round of inquiries from the North Exchange on December 9, questioning the necessity and rationality of its fundraising projects, particularly regarding the ability to absorb new production capacity and whether the projects align with market demand [3][25][29] - The company’s main business has shown rapid growth from 420 million yuan in 2022 to 730 million yuan in 2024, with net profit increasing from 63.44 million yuan to 104 million yuan during the same period [3][26] Group 2 - The company has faced pressure to meet net asset return requirements for its IPO, which has raised concerns about potential inventory pressure on its downstream distributors [3][26][37] - Kanghua Co., Ltd. has seen a decline in production capacity for its POCT products from 51.76 million units to 24.86 million units between 2022 and 2024, with a drop in capacity utilization from 103.13% to 94.99% [6][28][29] - The company’s expenses have decreased significantly compared to its revenue decline, with sales, management, and R&D expenses dropping by 30%, 11%, and 22% respectively, indicating a potential strategy to maintain profitability despite revenue challenges [12][34][35] Group 3 - Kanghua Co., Ltd. has been questioned about whether it has pressured distributors to increase revenue, as evidenced by a significant rise in distributor inventory levels, which reached 26.58% by mid-2025 [14][37][41] - The company’s main products have not experienced significant price drops post-collective procurement, maintaining high gross margins, but there are concerns about the sustainability of these margins in the face of increasing procurement pressures [21][43][44] - The overall environment for domestic in vitro diagnostic companies is challenging, with over 30% of listed companies expected to report losses in the first half of 2025, highlighting the competitive pressures in the industry [22][44]

Core Viewpoint - Kanghua Co., Ltd. has announced a significant reduction in its IPO fundraising amount and the number of investment projects, from 5.62 billion yuan to 3.68 billion yuan, a decrease of 35%, amid regulatory scrutiny and questions regarding the necessity and rationality of its fundraising projects [1][4][6]. Group 1: IPO and Fundraising Adjustments - The company has reduced its investment projects from five to three, cutting the fundraising amount for each project, resulting in an overall decrease in the total fundraising amount [1][4]. - The initial fundraising plan included five projects, with a total investment of 56.19 million yuan, but the revised plan now totals 42.66 million yuan [7][10]. - The company did not provide specific reasons for these adjustments, only stating it was in line with relevant laws and its actual development and future planning [1][4]. Group 2: Regulatory Scrutiny and Financial Performance - Kanghua Co., Ltd. received a second round of inquiries from the Beijing Stock Exchange regarding the necessity and rationality of its fundraising projects, particularly questioning the ability to achieve expected economic benefits [4][8]. - The company has shown rapid growth in its conventional business, with revenue increasing from 420 million yuan in 2022 to 730 million yuan in 2024, and net profit rising from 63.44 million yuan to 104 million yuan during the same period [4][6]. - Despite this growth, the company faces pressure to meet net asset return requirements for its IPO, which has raised concerns about potential inventory issues with its distributors [4][12]. Group 3: Inventory and Sales Concerns - There are suspicions that Kanghua Co., Ltd. may be pushing inventory onto its distributors, as evidenced by a significant increase in distributor inventory levels, which rose from 11.73% at the end of 2023 to 26.58% by mid-2025 [16][18]. - The company's sales performance has raised questions, as the proportion of sales from distributors has not aligned with typical inventory turnover rates, suggesting potential issues with sales recognition [16][21]. - The company has been asked to clarify the reasons for high inventory levels and whether there are any practices of pushing inventory to distributors [21]. Group 4: Impact of Centralized Procurement - Kanghua Co., Ltd. faces risks related to centralized procurement, particularly concerning its main product lines, which may be subjected to price reductions in the future [22][25]. - The company claims that the impact of centralized procurement on its products has been minimal so far, with some products even experiencing price increases post-procurement [23][24]. - However, the sustainability of high profit margins in the face of increasing procurement pressures remains uncertain, especially as its POCT products are likely to face centralized procurement soon [25].

Core Viewpoint - The article discusses the second round of inquiry by the Beijing Stock Exchange regarding the IPO of Shandong Kanghua Biomedical Technology Co., Ltd., focusing on key operational risks and issues related to the company's business practices and financial management [1]. Group 1: Inquiry Focus Areas - The inquiry highlights six main areas of concern, including post-IPO performance decline risk, adequacy of distributor management and cash flow verification, reasonableness of large inventory impairment provisions, related party transactions with companies controlled by the actual controller's relatives, and the necessity and rationality of fundraising projects [1]. - The actual controllers of Kanghua, Yang Zhiting, Wang Aixiang, and Yang Fan, collectively hold 90.07% of the shares, indicating a high concentration of ownership [2]. Group 2: Related Party Transactions - The inquiry emphasizes potential competition and related party transactions involving seven companies controlled by Yang Zhiting's brother and son, which operate in similar fields as Kanghua, leading to overlapping sales regions and shared suppliers and customers [2]. - The report indicates that there are 18 overlapping suppliers and 6 overlapping customers between Kanghua and the seven companies, raising concerns about the nature of these relationships [2]. Group 3: Financial and Operational Analysis - The Beijing Stock Exchange requests detailed explanations regarding the revenue, profit, and sales figures related to overlapping customers and suppliers, as well as the fairness of pricing in transactions between Kanghua and the related companies [3]. - The inquiry also seeks clarification on whether there are any plans for Kanghua to acquire the related companies and the nature of financial transactions between them, assessing the potential for profit transfer [3].

Core Viewpoint - The company reported a decline in revenue for 2024, primarily due to price reductions in biochemical reagents resulting from domestic IVD centralized procurement, but managed to achieve a slight increase in net profit, indicating effective cost control [3][4]. Financial Performance - In 2024, the company achieved total revenue of 1.659 billion yuan, a year-on-year decrease of 4.75% - The net profit attributable to shareholders was 533 million yuan, reflecting a year-on-year increase of 1.70% - The net profit excluding non-recurring items was 521 million yuan, up 1.93% year-on-year - In Q4 2024, the company reported a single-quarter revenue of 422 million yuan, down 17.01% year-on-year, while the net profit attributable to shareholders was 159 million yuan, an increase of 4.48% [3][4]. Operational Insights - The company's revenue decline was mainly influenced by the significant drop in biochemical reagent prices due to centralized procurement, which exerted pressure on the biochemical business line - Despite the revenue decline, the net profit showed a quarter-on-quarter increase of 29.5% in Q4, indicating improving profitability [4]. R&D and Product Development - The company has increased its R&D investment, with a research and development expense ratio of 11.36% in 2024, up 2.01 percentage points year-on-year - By the end of 2024, the company obtained 379 medical device registration certificates, up from 294 at the end of 2023, covering various fields including biochemistry, coagulation, chemiluminescence, blood typing, and POCT - The company also added 19 new patents and received approvals for multiple pathology, biochemistry, coagulation, and chemiluminescence reagent products, enhancing its product portfolio [5]. Strategic Initiatives - The subsidiary, Mai Xin Bio, is focusing on core technologies in pathological diagnosis and is expanding into areas such as companion diagnostics and pathology AI - Mai Xin Bio is also actively pursuing international markets, working on product qualification in mature markets like Europe and the US, as well as emerging markets in the Middle East and Southeast Asia, thereby entering a new phase of internationalization [6].